Effectiveness and safety of anti-SARS-COV-2 convalescent plasma in the treatment of the early phase of new coronavirus infection (COVID-19) in hospitalized risk patients: a randomized interventional clinical study

This is a randomized clinical study that seeks to demonstrate the safety and effectiveness of the use of plasma from recovered COVID-19 patients in hospitalized patients. In the study, the benefit of the administration of this plasma will be compared at two different moments in the evolution of the COVID infection. After treatment with plasma, the clinical, radiological and virological evolution will be compared between groups of patients. The early administration of convalescent plasma is expected to prevent the progression to severe forms of COVID-19 disease, reducing hospital stay, the need for ICU and mechanical ventilation.